Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
STAT1 regulated ILF2 complex interacting long non-coding RNA (SLEAR) is a human gene encoding a long non-coding RNA that interacts with the ILF2 complex and is regulated by STAT1, a key transcription factor in cytokine signaling pathways[1][2][3][6][7][8]. SLEAR is also known as FLJ42969 and SLE-associated RNA; the latter reflects its association with systemic lupus erythematosus, suggesting potential immunoregulatory functions. As a lncRNA, SLEAR is involved in RNA-mediated regulation of transcription and possibly immune functions, but it is not considered a classical therapeutic target like a receptor, enzyme, transporter, or druggable protein[2][7][8]. There is currently no evidence in available sources for direct druggability, specific small-molecule interactions, or well-established mechanisms of action for pharmacologic intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on STAT1 regulated ILF2 complex interacting long non-coding RNA (SLEAR).